BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAFV600 mutated melanoma, are currently explored in combination with various immunotherapies, notably checkpoint inhibitors and adoptive transfer of receptor-transfected T cells. Since two BRAFi/MEKi combinations with si...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jan Dörrie, Lek Babalija, Stefanie Hoyer, Kerstin F. Gerer, Gerold Schuler, Lucie Heinzerling, Niels Schaft
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2018-01-01
Colecção:International Journal of Molecular Sciences
Assuntos:
BRAF inhibitor
MEK inhibitor
kinase inhibitor
CAR-T cell
dabrafenib
trametinib
vemurafenib
cobimetinib
melanoma
immunotherapy
Acesso em linha:http://www.mdpi.com/1422-0067/19/1/289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados